Analysts Set Enovis Co. (NYSE:ENOV) PT at $62.75

Posted by on Apr 28th, 2023

Shares of Enovis Co. (NYSE:ENOV – Get Rating) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $62.75.

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $65.00 price target on shares of Enovis in a research report on Tuesday, March 28th. Evercore ISI upped their price target on shares of Enovis to $68.00 in a research note on Tuesday, January 3rd. Finally, Robert W. Baird cut their price target on shares of Enovis from $68.00 to $64.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th.

Enovis Stock Performance

Enovis stock opened at $57.87 on Tuesday. The company’s 50-day moving average price is $55.17 and its 200-day moving average price is $55.14. Enovis has a twelve month low of $43.88 and a twelve month high of $68.15. The company has a quick ratio of 0.65, a current ratio of 1.41 and a debt-to-equity ratio of 0.01. The company has a market cap of $3.15 billion, a PE ratio of -289.35 and a beta of 2.01.

Enovis (NYSE:ENOV – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.69 by $0.03. The company had revenue of $409.00 million for the quarter, compared to the consensus estimate of $415.79 million. Enovis had a negative net margin of 0.46% and a positive return on equity of 3.30%. The firm’s revenue was down 60.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.77 EPS. On average, equities research analysts forecast that Enovis will post 2.2 EPS for the current fiscal year.

Insiders Place Their Bets

In other Enovis news, CFO Phillip Benjamin (Ben) Berry sold 600 shares of Enovis stock in a transaction dated Monday, March 20th. The shares were sold at an average price of $51.84, for a total transaction of $31,104.00. Following the transaction, the chief financial officer now directly owns 20,868 shares of the company’s stock, valued at $1,081,797.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Brady Shirley sold 1,490 shares of Enovis stock in a transaction that occurred on Tuesday, February 21st. The shares were sold at an average price of $62.11, for a total value of $92,543.90. Following the completion of the transaction, the chief operating officer now owns 47,965 shares in the company, valued at $2,979,106.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Phillip Benjamin (Ben) Berry sold 600 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $51.84, for a total transaction of $31,104.00. Following the sale, the chief financial officer now owns 20,868 shares of the company’s stock, valued at approximately $1,081,797.12. The disclosure for this sale can be found here. Insiders have sold 64,485 shares of company stock valued at $3,658,181 over the last ninety days. Company insiders own 5.10% of the company’s stock.

Institutional Trading of Enovis

Institutional investors and hedge funds have recently bought and sold shares of the business. SummerHaven Investment Management LLC grew its stake in shares of Enovis by 1.4% during the 4th quarter. SummerHaven Investment Management LLC now owns 14,372 shares of the company’s stock worth $769,000 after purchasing an additional 205 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in shares of Enovis by 1.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 13,926 shares of the company’s stock worth $745,000 after acquiring an additional 209 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in shares of Enovis by 0.3% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 72,096 shares of the company’s stock worth $3,321,000 after acquiring an additional 216 shares during the period. Texas Permanent School Fund lifted its holdings in shares of Enovis by 0.7% during the 3rd quarter. Texas Permanent School Fund now owns 34,213 shares of the company’s stock worth $1,576,000 after acquiring an additional 237 shares during the period. Finally, Gamco Investors INC. ET AL lifted its holdings in shares of Enovis by 3.2% during the 4th quarter. Gamco Investors INC. ET AL now owns 8,523 shares of the company’s stock worth $456,000 after acquiring an additional 266 shares during the period. Hedge funds and other institutional investors own 96.73% of the company’s stock.

About Enovis

(Get Rating)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

See Also

Analyst Recommendations for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.